Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O’Hagan et al.

Grobler, Anna Christina.Abdool Karim, Salim Safurdeen.2013-06-252013-06-2520122012Grobler, A., Abdool Karim, S.S. 2012. Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O’Hagan et al. AIDS 26 (17) p.2261.0269-9370http://dx.doi.org/10.1097/QAD.0b013e328355ce08http://hdl.handle.net/10413/9195No abstract available.enClinical trials--Evaluation.HIV infections--Treatment.HIV infections--Drug therapy.Patient compliance.CAPRISA 004 microbicide trial.Drug adherence.Declining adherence is a more likely explanation than frailty of the apparent decline in efficacy in the CAPRISA 004 trial: response to O’Hagan et al.Peer reviewed journal article